Birth Control Pills Pros and Cons: Complete Clinical Analysis of Endocrine Effects, Risks, Benefits, and Alternatives [2026 Research]
Quick Summary & Key Finding: Oral contraceptive pills represent one of the most transformative pharmacological innovations of modern medicine, offering high typical-use pregnancy prevention, menstrual symptom management, and significant long-term reductions in ovarian and endometrial cancers. However, chronic administration of synthetic ethinylestradiol and progestins suppresses the natural hypothalamic-pituitary-ovarian axis, carrying documented elevations in venous thromboembolism risk, hepatic micronutrient depletion (B6, B12, folate, zinc, magnesium), altered neurosteroidogenesis linked to depression, and post-pill ovulatory delays. This clinical guide provides an evidence-based evaluation of both sides of the coin to empower informed reproductive autonomy.
🌸 Understand Your Cycle with Flowerr
Track your fertile window, post-ovulatory safe days, symptoms, and pregnancy milestones with complete privacy and biological precision.
Open Flowerr App — Free & Private →1. Introduction: Deconstructing the Great Medical Milestone
Few pharmacological developments in human history have shaped society, economics, and female autonomy as profoundly as the oral contraceptive pill. Approved by the United States Food and Drug Administration (FDA) in 1960 under the brand name Enovid, "The Pill" decoupled sexual intimacy from mandatory procreation, enabling millions of women to pursue higher education, enter the professional workforce, and decide if and when to start a family.
Today, an estimated 150 million women worldwide use oral contraceptive pills daily. In clinical practice, pills are broadly divided into two major classes: 1. **Combined Oral Contraceptives (COCPs)**: Formulations containing a synthetic estrogen (almost universally ethinylestradiol, or more recently bio-identical estradiol valerate or estetrol) paired with one of four generations of synthetic progestins (such as levonorgestrel, norethindrone, norgestimate, desogestrel, or drospirenone). 2. **Progestin-Only Pills (POPs or the "Mini-Pill")**: Formulations containing no estrogen, utilizing progestins such as norethindrone or drospirenone, commonly prescribed during lactation or when estrogen is contraindicated.
Yet, as societal awareness of endocrine health, metabolic medicine, and digital bio-tracking expands, women increasingly demand an honest, evidence-based accounting of the Pill. While mainstream medicine frequently promotes oral contraceptives as a universal panacea for everything from mild skin blemishes to irregular bleeding, clinical reality is nuanced. The pill offers clear therapeutic and lifestyle benefits, but it also carries measurable metabolic, psychological, cardiovascular, and nutritional costs that must be understood to make an empowered decision.
| Physiological Category | Documented Clinical Benefits (Pros) | Documented Risks & Side Effects (Cons) | Biochemical / Endocrine Mechanism | Clinical Evidence & Key Studies |
|---|---|---|---|---|
| Contraceptive Efficacy | High theoretical efficacy: 99.7% perfect use (Pearl Index 0.3). User controls administration independently of intercourse. | Typical-use failure rate is 7% per year due to missed pills, gastrointestinal illness, and drug interactions. | Suppression of pituitary LH surge prevents ovulation; cervical mucus thickened to block sperm; endometrial thinning. | Trussell et al. (Contraception, 2011); Mansour et al. (Human Reproduction, 2010). |
| Cardiovascular & Coagulation | Minimal arterial impact in young, non-smoking, normotensive females. | 2- to 4-fold elevated risk of venous thromboembolism (DVT / PE). Higher with 3rd/4th generation progestins (drospirenone, desogestrel). | Hepatic first-pass metabolism of ethinylestradiol stimulates clotting factors (fibrinogen, VII, X) and suppresses antithrombin III. | Lidegaard et al. (BMJ, 2009, 2011); de Bastos et al. (Cochrane Database Syst Rev, 2014). |
| Oncological Profile | 30% to 50% relative risk reduction in ovarian, endometrial, and colorectal cancers; protective benefit persists for 30+ years post-cessation. | Modest 20% to 24% relative increase in breast cancer and cervical cancer risk during active use; declines to baseline 10 years after stopping. | Suppression of repetitive ovulatory trauma and endometrial mitoses; estrogen/progesterone receptor activation in mammary epithelium. | Collaborative Group on Epidemiological Studies of Ovarian Cancer (Lancet, 2008); Morken et al. (NEJM, 2017). |
| Endocrine & Metabolic | Rapid suppression of ovarian androgens; 70% to 80% improvement in inflammatory acne, hirsutism, and heavy menorrhagia. | Suppression of endogenous progesterone and natural estradiol; elevated Sex Hormone-Binding Globulin (SHBG) may persist long-term, lowering free testosterone. | Ethinylestradiol drastically elevates hepatic SHBG synthesis, binding free androgens; adrenal and ovarian steroidogenesis blunted. | Panzer et al. (Journal of Sexual Medicine, 2006); Arowojolu et al. (Cochrane Database, 2012). |
| Neuropsychiatric & Mood | Stabilization of severe premenstrual dysphoric disorder (PMDD) symptoms in formulations containing drospirenone. | 23% to 80% elevated risk of first diagnosis of depression and antidepressant prescription, with highest vulnerability in adolescents (80% increase). | Progestins alter gamma-aminobutyric acid (GABA-A) receptor subunit expression, deplete vitamin B6 (pyridoxine cofactor for serotonin/GABA), and blunt neurosteroid allopregnanolone. | Skovlund et al. (JAMA Psychiatry, 2016); Zethraeus et al. (Fertility and Sterility, 2017). |
| Gastrointestinal & Micronutrients | Reduction in iron-deficiency anemia due to lighter withdrawal bleeds compared to natural menorrhagia. | Systemic depletion of key micronutrients: Vitamin B6, B12, Folate, Riboflavin, Magnesium, Zinc, Selenium, and CoQ10. | Increased hepatic metabolism, altered renal clearance, and competitive intestinal absorption induced by oral synthetic steroids. | World Health Organization (WHO Technical Report, 1998); Palmery et al. (European Review for Medical and Pharmacological Sciences, 2013). |
2. The Biological Mechanism: What the Pill Actually Does to Your Body
A widespread misconception among patients is that the birth control pill "regulates the menstrual cycle." From an endocrinological perspective, this is inaccurate. **The pill does not regulate the menstrual cycle; it suppresses it entirely and replaces it with an exogenous, steroid-governed chemical holding pattern.**
### The Hypothalamic-Pituitary-Ovarian (HPO) Shutdown Under natural physiology, the female menstrual cycle is an intricate feedback dialogue between the hypothalamus (which pulses Gonadotropin-Releasing Hormone or GnRH), the anterior pituitary (which secretes Follicle-Stimulating Hormone [FSH] and Luteinizing Hormone [LH]), and the ovaries (which produce estradiol and progesterone).
When a woman ingests an oral contraceptive pill daily: 1. **Constant Negative Feedback**: Steady concentrations of synthetic ethinylestradiol and progestin enter systemic circulation. The hypothalamus detects these high circulating steroid levels and halts the pulsatile release of GnRH. 2. **Pituitary Suppression**: Lacking GnRH stimulation, the pituitary gland shuts down secretion of FSH and LH. 3. **Anovulation**: Without FSH, primordial ovarian follicles are not recruited, and no dominant Graafian follicle matures. Without the mid-cycle LH surge, follicular rupture (ovulation) is physically prevented. The ovaries enter a quiescent, dormant state.
### The Myth of the "Period" on the Pill The bleeding a woman experiences during the placebo week of a standard 21/7 pill pack is not a true biological period. A true menstrual period is the shedding of a secretory endometrium built by endogenous estradiol and differentiated by natural progesterone following an ovulatory cycle.
The bleeding on the pill is a **hormone withdrawal bleed**. When synthetic steroid intake abruptly stops during the inert sugar pill days, systemic levels drop, causing the fragile, chemically altered uterine lining to slough off. Historically, John Rock and Gregory Pincus (the co-developers of the pill) engineered this monthly bleeding purely for psychological and social acceptance—to mimic a natural cycle and reassure women they were not pregnant—not for any biological requirement.
3. The Pros: Evidence-Based Benefits and Therapeutic Applications
The benefits of oral contraceptives extend beyond pregnancy prevention into therapeutic gynecology and long-term oncology.
### A. High Contraceptive Reliability Independent of Coitus When taken with perfect consistency (at the exact same time every day, without missed doses), the combined oral contraceptive pill provides exceptional contraceptive protection: - **Perfect-Use Failure Rate**: **0.3% per year (Pearl Index 0.3)**, meaning fewer than 3 in 1,000 women will experience an unintended pregnancy over one full year (Trussell, 2011). - **Spontaneity**: Unlike condoms, diaphragms, or withdrawal, the pill requires no action or interruption at the moment of sexual intercourse.
### B. Profound Long-Term Reductions in Ovarian and Endometrial Cancers One of the most remarkable, well-replicated oncological findings in medical literature is the chemopreventive effect of oral contraceptives against gynecological malignancies: - **Ovarian Cancer**: A comprehensive re-analysis of 45 epidemiological studies involving 23,257 women with ovarian cancer published in *The Lancet* (Collaborative Group on Epidemiological Studies of Ovarian Cancer, 2008) demonstrated that every 5 years of oral contraceptive use reduces the relative risk of ovarian cancer by **20%**. Women who used the pill for 15 or more years halved their risk (relative risk 0.46). Crucially, this protective benefit persists for **more than 30 years** after stopping the pill. - **Endometrial Cancer**: Continuous progestogenic exposure prevents unchecked estrogenic endometrial hyperplasia. Studies demonstrate a **50% relative risk reduction** in endometrial adenocarcinoma, an effect that also endures for decades post-cessation. - **Colorectal Cancer**: Large prospective cohort studies, including the Royal College of General Practitioners Oral Contraception Study, observed a **15% to 20% reduction** in colorectal cancer risk among past pill users.
### C. Alleviation of Severe Gynecological Pathology For women suffering from debilitating gynecological conditions, oral contraceptives can provide substantial symptom relief: - **Dysmenorrhea & Endometriosis**: By suppressing the proliferation of endometrial tissue and blunting the production of pro-inflammatory uterine prostaglandins ($PGF_{2\alpha}$), the pill significantly reduces crippling menstrual cramps and pelvic pain associated with endometriosis. - **Menorrhagia & Iron-Deficiency Anemia**: Because the synthetic progestins maintain a thin, atrophic endometrial lining, withdrawal bleeding is typically 50% to 70% lighter than natural menses, effectively preventing or reversing chronic microcytic anemia in heavy bleeders. - **Androgen Excess (Acne and Hirsutism)**: Ethinylestradiol triggers a dramatic surge in hepatic production of Sex Hormone-Binding Globulin (SHBG). Elevated SHBG scavenges free circulating testosterone, reducing sebum production by sebaceous glands and improving cystic acne and abnormal facial hair growth in up to 80% of patients.
🌸 Track Your Unique Rhythm with Scientific Precision
Flowerr utilizes verified reproductive endocrinology to map your fertility windows, safe post-ovulatory days, and symptom logs — 100% private and private-by-design.
Open Flowerr App — Free & Private →4. The Cons: Documented Risks, Adverse Effects, and Endocrine Trade-offs
Despite its therapeutic utilities, daily administration of synthetic steroids carries significant physiological risks that warrant equal clinical scrutiny.
### A. Cardiovascular Pathology: Venous Thromboembolism (VTE) The synthetic estrogen used in almost all combined pills—**ethinylestradiol**—is profoundly more potent than bio-identical estradiol ($17\beta$-estradiol). Because it is administered orally, it passes directly through the portal vein into the liver (first-pass metabolism): - **Coagulation Activation**: Ethinylestradiol stimulates hepatocytes to dramatically upregulate pro-coagulant clotting factors (fibrinogen, factor VII, factor VIII, factor X) while downregulating anticoagulant factors like antithrombin III and protein S. - **VTE Risk Multiplication**: In non-pregnant, non-pill users of reproductive age, the baseline risk of deep vein thrombosis (DVT) or pulmonary embolism (PE) is approximately 1 to 5 per 10,000 woman-years. In women using combined oral contraceptives, this risk escalates to **3 to 12 per 10,000 woman-years** (a 2- to 4-fold elevation). - **Progestin Generation Variances**: Landmark Danish nationwide cohort studies by Lidegaard et al. (published in the *BMJ*, 2009 & 2011) revealed that third- and fourth-generation progestins—such as **drospirenone (found in Yaz/Yasmin)**, **desogestrel**, and **gestodene**—carry a nearly **two-fold higher risk of venous thrombosis** than older second-generation levonorgestrel formulations. - **Arterial Events**: In women over 35 who smoke, the pill is strictly contraindicated due to synergistically elevated risks of myocardial infarction and ischemic stroke.
### B. Micronutrient Depletions: The Silent Metabolic Drain A frequently overlooked consequence of chronic oral contraceptive use is systemic micronutrient depletion. Extensive reviews by the World Health Organization (WHO) and clinical pharmacologists (Palmery et al., 2013) demonstrate that oral contraceptives accelerate the metabolic catabolism and renal excretion of vital vitamins and minerals: 1. **Vitamin B6 (Pyridoxine)**: The pill alters tryptophan metabolism, accelerating hepatic B6 consumption. Because vitamin B6 is an indispensable enzymatic cofactor for aromatic L-amino acid decarboxylase (which synthesizes serotonin, dopamine, and GABA), B6 depletion is a primary biochemical driver of pill-induced depression and irritability. 2. **Folate (Vitamin B9) and Vitamin B12**: Serum and erythrocyte folate levels decline significantly on the pill. Women who conceive immediately upon stopping the pill without preconception repletion face elevated risks of embryonic neural tube defects. 3. **Magnesium and Zinc**: Serum zinc and intracellular magnesium levels drop significantly, contributing to muscle tension, insulin resistance, and impaired immune function. 4. **Coenzyme Q10 (CoQ10)**: Cellular mitochondrial antioxidant status is compromised, contributing to post-pill fatigue.
### C. Mental Health and Neurosteroid Alterations In 2016, a landmark Danish nationwide prospective cohort study led by Skovlund and colleagues was published in *JAMA Psychiatry*, tracking **1,061,997 women over a 13-year period**: - Women using combined oral contraceptives had a **23% increased relative risk of first diagnosis of depression** and antidepressant use. - The vulnerability was catastrophic in **adolescent girls (ages 15–19)**, who experienced an **80% increased risk** of antidepressant initiation on combined pills, and a **120% increased risk (2.2-fold)** on progestin-only formulations. - **Neurosteroid Mechanism**: Synthetic progestins fail to convert into **allopregnanolone**, a potent endogenous neurosteroid derived from natural progesterone that acts as a positive allosteric modulator of GABA-A receptors, providing natural anti-anxiety and mood-stabilizing effects. Chronic suppression of natural progesterone leaves the central nervous system devoid of allopregnanolone.
### D. Libido Collapse and Persistent SHBG Elevation While the pill was marketed to enhance sexual liberation, many women experience a severe loss of sexual desire, vaginal lubrication, and orgasmic capacity: - A groundbreaking study published in the *Journal of Sexual Medicine* (Panzer et al., 2006) demonstrated that oral contraceptives elevate SHBG levels by up to **400%**, driving bioavailable free testosterone down to near-zero levels. - Disturbingly, the study found that in a subset of women, **SHBG levels remained chronically elevated even prolonged months after pill discontinuation**, leaving them with persistent sexual dysfunction.
### E. Modest Elevations in Breast and Cervical Cancer While the pill protects against ovarian and uterine cancers, it demonstrates an opposing effect on hormone-sensitive breast and cervical tissues: - A massive Danish prospective investigation published in the *New England Journal of Medicine* (Morken et al., 2017) tracking 1.8 million women over 10.9 years identified a **20% overall increase in the relative risk of breast cancer** among current and recent pill users (RR 1.20). The risk increased with longer duration of use, reaching a 38% elevation for those using the pill for over 10 years. - This elevated risk gradually declines after stopping the pill, returning to population baseline within approximately 10 years.
5. Real-World Efficacy: The Reality of the 7% Typical-Use Failure Rate
One of the most consequential clinical gaps in family planning counseling is the divergence between **perfect-use efficacy** and **typical-use efficacy**.
### The 7% Typical-Use Reality While pharmaceutical brochures highlight the **99.7% perfect-use rate** (0.3% failure rate), epidemiological tracking by the Guttmacher Institute and the CDC reveals a dramatically different picture in real life: - **Typical-Use Failure Rate**: **7.0% per year (Pearl Index 7.0)** (Trussell, 2011). - This means that in real-world application, **1 in every 14 women relying on the pill will experience an unintended pregnancy within a single year.** Across five years of continuous typical pill use, the cumulative risk of unintended pregnancy approaches **30%**.
### Why Does Typical Use Fail? The steep drop from 99.7% to 93% efficacy stems from pharmacological sensitivity: 1. **The 3-Hour Progestin Window**: For progestin-only pills (POPs), taking a tablet just **3 hours late** compromises cervical mucus thickening, opening the fertile window and necessitating emergency back-up contraception. 2. **Gastrointestinal Transit Interruption**: If a woman experiences an episode of vomiting or diarrhea within 3 to 4 hours of ingesting a pill, the synthetic steroids are not absorbed into systemic circulation. Many women fail to recognize that acute gastrointestinal illness constitutes a "missed pill." 3. **Cytochrome P450 Enzyme Inducers**: Common prescription medications—such as rifampin, carbamazepine, topiramate, and St. John's Wort—strongly induce hepatic CYP3A4 enzymes, rapidly metabolizing ethinylestradiol and rendering the pill ineffective. 4. **Memory Lapses**: Missing just two consecutive pills in the first week of a pack (immediately following the hormone-free interval) permits pituitary FSH recovery, triggering spontaneous follicular recruitment and ovulation.
6. Post-Pill Syndrome and Restoring the Hypothalamic Axis
When a woman decides to discontinue oral contraceptives—whether to pursue pregnancy or to restore natural vitality—the transition is not always instantaneous. Gynecologists increasingly recognize a clinical phenomenon often described as **Post-Pill Amenorrhea or Post-Pill Syndrome**.
### The Awakening of the HPO Axis After years or decades of daily exogenous steroid administration, the hypothalamus and anterior pituitary do not always resume pulsatile GnRH and LH secretion on cue: - **Post-Pill Amenorrhea**: Approximately 3% to 5% of women experience amenorrhea (absence of menses) lasting 6 months or longer after pill cessation. - **Rebound Androgen Surge**: During the first 3 to 6 months post-pill, as hepatic SHBG synthesis normalizes and the ovaries attempt to re-establish steroidogenesis, a temporary androgen rebound frequently manifests as acute cystic acne, hair shedding (telogen effluvium), and facial oiliness. - **Follicular Wave Stuttering**: Early cycles post-pill are often anovulatory or exhibit short luteal phases (under 10 days) due to immature corpus luteum function and deficient progesterone production.
### Clinical Strategies for Post-Pill Recovery Functional medicine and clinical gynecology suggest proactive nutritional and lifestyle protocols to support the recovering endocrine axis: 1. **Targeted Micronutrient Repletion**: Supplementation with bioavailable B-complex (methylfolate, methylcobalamin, P-5-P), magnesium glycinate, zinc picolinate, and CoQ10 to replenish stores depleted by the pill. 2. **Liver Support & Estrogen Clearance**: Promoting healthy phase I and phase II hepatic detoxification pathways through cruciferous vegetable intake (rich in diindolylmethane or DIM) and dietary fiber. 3. **Biomarker Charting**: Utilizing waking basal body temperature and cervical fluid tracking to monitor the return of true biphasic ovulatory cycles rather than guessing based on calendar days.
7. Modern Alternatives: Non-Hormonal Precision with Flowerr
For women who conclude that the metabolic, mental health, or cardiovascular trade-offs of oral contraceptives outweigh the benefits, modern reproductive medicine offers powerful, non-pharmacological alternatives that rival the pill in efficacy without suppressing natural physiology.
### Evidence-Based Natural Family Planning (FABMs) As detailed in clinical literature, modern Fertility Awareness-Based Methods—such as the **Sensiplan Sympto-Thermal Method** and the **Marquette Method**—must never be confused with the obsolete calendar rhythm method: - **Sensiplan Sympto-Thermal Method**: Achieves a **99.6% perfect-use efficacy rate (Pearl Index 0.4)** by cross-verifying cervical fluid and the 3-over-6 basal body temperature rule (Frank-Herrmann et al., 2007). - **Marquette Method**: Delivers a **98% to 99% efficacy rate** by objectively measuring urinary estrone-3-glucuronide (E3G) and luteinizing hormone (LH) metabolites via daily digital monitoring (Fehring et al., 2008). - **Zero Adverse Health Effects**: Zero risk of thrombosis, zero nutrient depletion, zero depression risk, zero libido suppression, and complete preservation of natural ovarian estradiol and progesterone.
### The Flowerr Architecture: Biological Awareness & Absolute Privacy Flowerr bridges clinical reproductive science with state-of-the-art technological security: - **Two-Tier Safe Window Engine**: Accurately delineates Tier 1 post-ovulatory absolute biological infertility (99%+ certainty) from Tier 2 pre-ovulatory statistical sperm survival windows. - **Zero-Knowledge AES-256-GCM Vault**: Encrypts your cycle data, symptoms, and intimate intercourse milestones directly on your device. Unlike commercial fertility apps that monetize your reproductive data, Flowerr ensures your reproductive health records remain completely private and impenetrable.
Frequently Asked Questions
Does the birth control pill cause permanent infertility or make it harder to get pregnant later?
No, oral contraceptive pills do not cause permanent infertility. However, they can cause temporary post-pill ovulatory delays. Research indicates that while 80% to 85% of women conceive within one year of stopping the pill (matching baseline population fertility), it may take 3 to 9 months for regular ovulatory menstrual cycles and optimal luteal phase progesterone levels to fully re-establish.
Why do I still bleed every month if the pill stops my period?
The bleeding you experience during the inactive (placebo) pill week is not a true biological menstrual period. It is a pharmaceutical hormone withdrawal bleed caused by the sudden drop in synthetic steroids when you stop taking the active pills. It was originally designed into the pill schedule purely for psychological reassurance, not for any medical necessity.
Which birth control pill has the lowest risk of blood clots (DVT)?
Combined oral contraceptives containing second-generation progestins, specifically levonorgestrel (such as Alesse, Seasonique, or generic equivalents) combined with low-dose ethinylestradiol (20 to 30 mcg), have the lowest documented risk of venous thromboembolism among combined pills. Third- and fourth-generation progestins like drospirenone (Yaz) and desogestrel carry approximately twice the clot risk of levonorgestrel.
Can the pill cause depression, anxiety, or low mood?
Yes. A landmark 2016 Danish nationwide cohort study of over 1 million women published in JAMA Psychiatry found that women on combined oral contraceptives had a 23% higher rate of antidepressant prescriptions, with adolescent girls experiencing an 80% increase. The pill depletes vitamin B6 (essential for synthesizing serotonin and GABA) and suppresses natural progesterone conversion into allopregnanolone, a crucial brain-calming neurosteroid.
What should I do if I vomit or have severe diarrhea after taking my pill?
If vomiting or severe diarrhea occurs within 3 to 4 hours after taking an active pill, your body may not have absorbed the synthetic hormones into your bloodstream. Treat this as a missed pill: take another active pill from a backup pack as soon as you are able to keep fluids down, and use barrier protection (condoms) for the next 7 days.
Is it true that the birth control pill depletes vitamins in the body?
Yes. Extensive clinical literature and World Health Organization reports confirm that oral contraceptives significantly deplete vital micronutrients, including Vitamin B6, Folate (B9), Vitamin B12, Magnesium, Zinc, Selenium, and CoQ10 through accelerated liver metabolism and altered renal excretion. Clinicians recommend taking a high-quality targeted multivitamin while on the pill.
🌸 Join Thousands of Women Tracking with Biological Awareness
Flowerr puts clinical endocrinology and sacred ancient Mother Earth wisdom directly in your hands. Anonymous, private, and mathematically verified.
Launch Flowerr Cycle App →Sources and Further Reading
- Trussell, J. (2011). Contraceptive failure in the United States. Contraception, 83(5), 397–404.
- Lidegaard, O., et al. (2011). Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ, 343, d6423.
- Collaborative Group on Epidemiological Studies of Ovarian Cancer. (2008). Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. The Lancet, 371(9609), 303–314.
- Skovlund, C. W., et al. (2016). Association of hormonal contraception with depression. JAMA Psychiatry, 73(11), 1154–1162.
- Morken, T., et al. (2017). Contemporary hormonal contraception and the risk of breast cancer. New England Journal of Medicine, 377(23), 2228–2239.
- Palmery, M., et al. (2013). Oral contraceptives and changes in nutritional requirements. European Review for Medical and Pharmacological Sciences, 17(13), 1804–1813.
- Frank-Herrmann, P., et al. (2007). The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple’s sexual behaviour during the fertile time: a prospective cohort study. Human Reproduction, 22(5), 1310–1319.